
CareSource
Innovations

6. **Dosage allowed/Quantity limit:** The starting weekly dose is 0.4 mg/kg intramuscularly, divided into two doses (0.2 mg/kg twice a week), for a minimum of 12 to 24 weeks until immune reconstitution is achieved.
   Then, the dose may be gradually adjusted down to maintain trough ADA activity over 30 mmol/hr/L, trough dAXP level under 0.02 mmol/L, and/or to maintain adequate immune reconstitution based on clinical assessment.
   Note: If transitioning from Adagen, see prescribing information.

If all the above requirements are met, the medication will be approved for 6 months.

For **reauthorization**:

1. Chart notes must show at least one of the following:
   a) Trough plasma ADA activity level of at least 30 mmol/hr/L
   b) Trough erythrocyte dAXP levels below 0.02 mmol/L
   c) Improved lymphocyte counts
   d) Improved clinical immune status (i.e., fewer/less severe infections compared to baseline); AND
2. Member meets one of the following:
   a) Revcovi is being used as a bridge prior to undergoing HSCT
   b) Member is not a candidate for HSCT or does not have a suitable donor
   c) Member has failed HSCT.

If all the above requirements are met, the medication will be approved for an additional 12 months.

CareSource considers Revcovi (elapegademase-lvlr) not medically necessary for the treatment of conditions that are not listed in this document. For any other indication, please refer to the Off-Label policy.

DATE	ACTION/DESCRIPTION
11/23/2021-(To	